NanoViricides, Inc.NNVCNYSE
Loading
R&D Expense Growth Recovery in ProgressRecovering
Percentile Rank43
Studio
Year-over-Year Change

Year-over-year research & development expense growth

Percentile
P43
Within normal range
vs 2Y Ago
0.2x
Contraction
Streak
1 yr
Consecutive growthRecovering
PeriodValue
20252.06%
2024-14.94%
202310.50%
2022-5.39%
202130.22%
2020-20.71%
201922.68%
2018-12.74%
201710.00%
201637.39%